Starts 21 Sept | 15 CPD hours | Join 650+ students who’ve already taken this course

Join our 6-Week Online Course

Fundamentals of Psychedelic-Assisted Therapies for Mental Health

Starts on 21 September 2025

Enrol now

Psychedelic medicine is reshaping mental health treatment

Master the research, protocols, and clinical frameworks of psychedelic medicine so you can better support your patients and prepare for the next paradigm in mental health.

 

Don't miss out - course starting soon!

00

DAYS

00

HOURS

00

MINS

00

SECS

What you'll learn

This is a 6-part online training program on the Fundamentals of Psychedelic-Assisted Therapies. 

The course is designed to educate a broad range of medical and mental health professionals, those with lived experience and consumers on the science and clinical use of psychedelics. 

This course will get you up to speed on these paradigm shifting treatments, and help you understand how these medicines will affect your practice, patients, families and communities. 

  • Learn from leaders in psychedelic medicine
  • 6x Weekly lectures from 21 September to 26 October 2025
  • Pre-reading material, additional learning resources and assessment of course learning outcomes
  • Lifetime access
  • Certificate of completion (15 CPD hours)

Who is it for?

  • Clinicians (GPs, psychiatrists, psychologists, nurses, social workers, psychotherapists)
  • Students & practitioners in training
  • Patients, families & the general public

If you fit one of these groups, this course is designed for you. 

What our students say

“This is the most thought-provoking course I've ever taken.”

Mark Wilbourn

“This course is an excellent introduction into the world of psychedelic-assisted therapy for clinicians and enthusiasts alike.”

Francis Dunne

Save my seat

Why did we create it?

 

As access to psychedelic medicine is opening up around the world, healthcare professionals and the general public are seeking reliable information about how psychedelic-assisted therapies work and what the potential benefits and drawbacks are. 

The Fundamentals of Psychedelic-Assisted Therapies is a collaboration between two leading international charities in the psychedelic space: Mind Medicine Australia and Drug Science. 

This course provides a solid foundation for anyone interested in psychedelic-assisted therapies. Healthcare professionals who are receiving questions from clients, those considering working in the psychedelic field and members of the general public will all find great value in this training. 

The course will begin on 21 September 2025.

Join us from:

Sydney: 6pm (AEST)

London: 9am (BST)

* Recordings will be made available for course members

Student testimonials

"Thanks for everything that Mind Medicine Australia does! For all the advocacy, facilitation of research and education. Prof David Nutt also said in his first lecture he stands under the shoulders of giants (referring to William James and others). I think that David, Peter Hunt and Tania de Jong are Giants themselves - of Leadership and Reason! I am certain in the future they will be written into the history annals with tremendous acclaim. They just need to continue on with their work in the face of adversity."

Fiona Webster

“I want to express my gratitude and satisfaction with the course. I found it both informative and truly inspiring. It has been a foundational experience, laying a strong basis for further growth and understanding. Thank you for putting together such a valuable learning journey!”

Maria Laura Mele

“The Fundamentals of Psychedelic-Assisted Therapies course has furthered my understanding on the potential mental health benefits of psychedelics while debunking myths which I thought were true. I thoroughly enjoyed learning so much about psychedelics in the six modules, including the science, history, evidence-based benefits, and future of psychedelic medicine.”

Dr Sean Knowles

“I found the Fundamentals of Psychedelic-Assisted Therapy Course to be incredibly in depth. Demystifying these substances that I had limited understanding of. Now I see the huge potential for healing using psychedelics in many medical practices. I found the course really awakened a yearning to learn more so I have enrolled in the Certificate of Psychedelic-Assisted Therapies course for 2025. As a Shaman I am really excited to be part of this new medical field that merges science and plant medicines.”

Kelly Smyth

Start learning

You'll learn about:

 

  • The evolution of psychedelic use: from Indigenous traditions to laboratory synthesis — and why prohibition began.

  • The neuroscience of psychedelics: how they act on the brain, and leading theories for their therapeutic effects.

  • A review of clinical evidence: what the literature shows for depression, PTSD, and other psychiatric conditions.

  • Therapy in practice: how psychedelic-assisted protocols are structured, and how they differ across medicines.

  • The practical role in psychotherapy: when and how these compounds are integrated into treatment.

  • Risks and limitations: what clinicians and patients must weigh before treatment.

  • Safety frameworks: the key considerations for ethical, effective psychedelic-assisted therapy.

  • A new paradigm for mental health: one that spans biology, psychology, and human experience.

  • The deep wisdom of Indigenous knowledge — and the importance of respect for these traditions.

  • The unique case of ketamine: its dual role as an antidepressant and a psychedelic medicine.

  • The legal landscape in Europe and Australia: current access pathways and emerging directions.

 

Course Outline

The Faculty:

The faculty is made up of leaders in the psychedelic field.

 

Prof David Nutt (UK)

Renowned researcher, policy advisor and author, Professor David Nutt, is currently Head of Neuropsychopharmacology at Imperial College London and the Chair of Drug Science. Under the leadership of Professor Nutt, the Psychedelic Research Group at Imperial College is one of the world’s foremost psychedelic research laboratories, publishing landmark research on psychedelic therapies and neuroimaging studies of the psychedelic state.

Dr Laurie Higbed (UK)

Dr. Laurie Higbed is an experienced clinical psychologist registered with the Health and Care Professions Council (HCPC) and a member of the Association of Clinical Psychologists (ACPUK). She has extensive experience as a lead therapist in clinical trials exploring MDMA and psilocybin assisted therapies for both mental health difficulties and substance use problems.

Dr Eli Kotler (AUS)

Dr. Eli Kotler has been on the forefront of psychedelic-assisted therapy (PAT) both in Australia and internationally, currently working at The Journey Clinic. He is the Australian Director of the Certificate of Psychedelic-Assisted Therapy (CPAT), run by Mind Medicine Australia. In 2021 he challenged the Victorian government in court to allow a patient to access PAT, and was the first psychiatrist in Australia to treat a patient with PAT.

Dr Lauren Macdonald (UK)

Dr Lauren Macdonald is a psychiatry doctor, psychedelic therapy guide and group facilitator. For the last few years she has been a clinical trial doctor at The Centre for Psychedelic Research (Imperial College London) investigating psilocybin-assisted therapy for anorexia-nervosa, chronic pain, and treatment-resistant depression.

Taita Juan Bautista (COL)

Taita Juan Bautista Agreda is a prominent figure within the Kamentsa lineage of the Amazon region of Colombia. He is renowned for his unwavering dedication to Indigenous rights, environmental stewardship, and community empowerment. His legacy is shaped by his service as a three-time governor of the Kamentsa nation.

Erika Salazar (COL)

Erika Salazar is a Colombian woman of indigenous ancestry, deeply rooted in the community and reservation of the Kamentsa Biya in Sibundoy Putumayo, as a dynamic advocate for the sacred medicines that bridge the modern and ancient worlds. Erika is the author of the book "Return to the Origins," a work that seeks to educate about sacred medicine and the cosmology of indigenous peoples.

Dr Julia King Olivier (Switzerland)

Julia is a board-certified psychiatrist and psychotherapist specialised in both adult and child/adolescent psychiatry. She integrates diverse therapeutic approaches—including psychodynamic therapy, EMDR, mindfulness, and ecopsychiatry workshops—into her practice.

Prof Celia Morgan (UK) 

Celia is a Professor of Psychopharmacology at the University of Exeter in the United Kingdom. Prof. Morgan is currently the lead on a state funded Phase 3 trial of ketamine-assisted therapy in AUD and ran the world's first trial of ketamine-assisted therapy.

Peter Hunt AM (AUS)

Peter Hunt AM is a former investment banker turned philanthropist and Chairman of Mind Medicine Australia, where he led the successful rescheduling of MDMA and psilocybin. He also founded Women’s Community Shelters and serves on several non-profit boards, driving initiatives for a fairer and more compassionate society.

CPD and Accreditation 

 

Students will receive a Certificate of Completion once they have completed all course content and assessment. You can claim 15 CPD hours with the college/association you're registered with.

 

Your First Step into Psychedelic Therapies

With $500 AUD Off CPAT™

We want your decision to join Fundamentals to be a simple one.

Enrol now and you’ll receive a $500 AUD discount on your Certificate in Psychedelic-Assisted Therapies (CPAT)™ fees if you decide to take your learning further.

That’s the equivalent of completing Fundamentals for just $99 AUD—an incredible opportunity to learn from world-renowned Australian and international experts at a fraction of the usual cost.

Starts 21 Sept | 15 CPD hours | Join 650+ students who’ve already taken this course

The Complete Fundamentals Program:

✔️ 6 live weekly sessions (21 Sept – 26 Oct)

✔️ 15 CPD hours + Certificate of Completion

✔️ Lifetime access to all materials

✔️ Recordings if you can’t attend live

✔️ $500 AUD credit toward CPAT™ (effective $99 course fee)

✔️ PayPal 4-in-6 payment plan option

Enrol today

Pick your preferred payment currency below.

$599 AUD

Australian Dollar

Secure my place

£315 GBP

British Pound

Secure my place

About Mind Medicine Australia 

Mind Medicine Australia is Australia’s leading not-for-profit organisation working on the use of medicinal psilocybin and MDMA-assisted therapies to treat a range of mental illnesses. Mind Medicine Australia exists to help alleviate the suffering and suicides caused by our accelerating mental illness epidemic in Australia, through expanding the treatment options available to medical practitioners and their patients. 

MMA works towards this goal by focusing on four strategic pillars: 

  • Awareness and knowledge building through education, events and webinars. 
  • Professional development, including the world-leading Certificate in Psychedelic-Assisted Therapies (CPAT)™ along with other workshops and courses.  
  • Supporting university research, education, funding, and development of clinical trials.  
  • Supporting patient access, affordable medicine supplies and the development of clinics. 

About Drug Science

Drug Science is the only completely independent, science-led drugs charity in the UK, uniquely bringing together leading drug experts from a wide range of specialisms to carry out ground-breaking research into drug harms and effects.  

Drug Science works to provide an evidence base free from political or commercial influence, creating the foundation for sensible and effective drug laws, and equipping the public, media and policymakers with the knowledge and resources to enact positive change.  

The Drug Science Medical Psychedelics Working Group, led by global experts in the field of psychedelic medicines, aims to create a rational and enlightened approach to psychedelic research and clinical treatment. The future of psychedelic medicine is extremely promising, and there is potential for the widespread application of psychedelic drugs within public health models. Drug Science works collaboratively and proactively with interdisciplinary partners to ensure that psychedelic medicines are developed for UK, EU and worldwide healthcare models. Our aim is to ensure that medical psychedelics can be used safely in an ethical and economically sustainable manner and demonstrate a potential for lasting therapeutic benefit.   

Our objectives are:  

  • Develop and deliver scientific research on psychedelic drugs  

  • Provide evidence that supports the removal of psychedelic drugs from Schedule 1 restrictions  

  • Work with regulatory bodies to ensure that relevant legislation is enacted to facilitate medical use of psychedelic drugs  

  • Promote destigmatisation and improved understanding of psychedelic drugs  

  • Provide evidence-based educational resources on psychedelic medicine for doctors, pharmacists, healthcare professionals and the general public  

Frequently Asked Questions